Vasocard en es it fr

Vasocard Brand names, Vasocard Analogs

Vasocard Brand Names Mixture

  • No information avaliable

Vasocard Chemical_Formula


Vasocard RX_link

Vasocard fda sheet

Vasocard FDA

Vasocard msds (material safety sheet)

Vasocard Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Vasocard Molecular Weight

387.433 g/mol

Vasocard Melting Point

273 oC

Vasocard H2O Solubility


Vasocard State


Vasocard LogP


Vasocard Dosage Forms


Vasocard Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Vasocard Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Vasocard Absorption

Essentially completely absorbed in man (90% bioavailability).

Vasocard side effects and Toxicity

LD50=259.3mg/kg (i.v. in mice)

Vasocard Patient Information

Vasocard Organisms Affected

Humans and other mammals